key: cord-0948891-mtvvhmwg
authors: Rossi, A.; Prochowski Iamurri, A.; Cerchione, C.; Gentili, N.; Danesi, V.; Altini, M.; Paganelli, G.; Barone, D.
title: PCN224 An Italian Experience: How the COVID-19 Era HAS Modified the Radiological Activity in a Cancer Hospital
date: 2020-12-31
journal: Value in Health
DOI: 10.1016/j.jval.2020.08.361
sha: e1a9e67f02d4cf23502344bb6c417ae461315af2
doc_id: 948891
cord_uid: mtvvhmwg

nan

Singhal M, 1 Nepal B, 1 Fisch MJ, 2 Debono D, 3 Grabner M, 1 Stephenson JJ, 1 Churchill C, 4 Gable J, 4 Zhu Y, 4 Stenger K, 4 Cuyun Carter G 4 1 HealthCore, Inc., Wilmington, DE, USA, 2 AIM Specialty Health, Chicago, IL, USA, 3 Anthem Inc., Indianapolis, IN, USA, 4 Eli Lilly and Company, Indianapolis, IN, USA Objectives: We conducted a retrospective analysis using a commercially insured US population to describe patient characteristics and treatment patterns including adherence/persistence among women with mBC using oral CDK4&6i. Methods: The HealthCore Integrated Research Database (HIRD®) containing claims and enrollment data from a large commercial US payer was used to identify adult women with mBC and CDK4&6i fills (abemaciclib, palbociclib, ribociclib) between Jan-2012 and Jun-2018. Patients were required to have $6 months of health plan enrollment before (baseline) and after (follow-up) the earliest CDK4&6i fill. Patients with other kinase inhibitor use or claims for other primary cancers at baseline were excluded. Metastases were identified via ICD-9/10-CM codes. Line of therapy was based on presence/ absence of medication claims at baseline. Adherence was measured via proportion of days covered (PDC$80%) over 6-months follow-up, and a 60-day gap was used for discontinuation. No statistical testing was conducted. Results: Among 1,748 CDK4&6i users mean (standard deviation, SD) age was 60 (11.4) years. Approximately 19% were enrolled in managed Medicare plans. At baseline, metastases were found most frequently in the bone (77%), followed by lymph nodes (33%), liver (21%), and lung (19%) . Approximately 72% used CDK4&6i as 2 nd -line+ treatment, usually following endocrine therapy (62%) or chemotherapy (18%). Mean (SD) number of concomitant all-cause drug classes (excluding CDK4&6i) over baseline and follow-up was 9 (4.9). Mean (SD) PDC to CDK4&6i was 0.75 (0.24) and 58% of patients were classified as adherent; 23% of patients discontinued over 6-months follow-up and among those, mean (SD) time to discontinuation was 67 (33.2) days. Conclusions: Over a six-month period approximately two-thirds of CDK4&6i initiators were adherent and a quarter discontinued. We observed high levels of polypharmacy. Future research is needed to investigate longer-term adherence/persistence and factors that influence these measures to enable development of solutions to optimize outcomes for patients. Bioclinic Oncology Unit of Thessaloniki, Thessaloniki, Greece, 5 Pharmecons Easy Access, Varkiza, Greece Objectives: At a time when most cancer incidences are falling, the annual incidence of melanoma has risen as rapidly as 4-6% in many European countries, with a substantial economic burden in advanced stages. The purpose of this study is the investigation of treatment pathways and healthcare resource use of advanced BRAFmutated melanoma in Greece. Methods: This study is based on the information collected by an expert panel comprising of 3 oncologists of major public and private melanoma centers around Greece. A 3-round survey was undertaken, according to a modified Delphi method. The treatment phases studied were: pre-progression; disease progression and terminal care. Oncology drug costs, medical visits, laboratory tests, imaging examinations, hospitalizations, radiotherapy/surgery and concomitant medications were the resources considered in the context of the Greek National Services Organization (EOPYY). Results: The most common disease management scenario (80% of cases) in Greece for patients of stage IV BRAF V600 mutated melanoma was: targeted therapies as first line treatment at 95% and 5% for immunotherapies, followed by 95% immunotherapies and 5% targeted therapies as second line and third line treatment at 65% of cases. At third line several therapeutic options were applied, immunotherapies, monotherapy and combination therapies, targeted therapies, chemotherapy and others. The weighted annual cost of treatment was 86.516,88 V for first line treatment at list price and around 41.679,50 based on the negotiated price*. At second line the cost of treatment has been estimated at 21.646,7V and 58.651,81V for third line treatment for the most commonly used management scenarios. Conclusions: Metastatic BRAF mutant melanoma requires prolonged and costly treatment but new therapies managed to substantially increase life expectancy. Identifying the appropriate treatment options in order to optimize health outcomes should be an important priority in healthcare system. *Assumption taking into consideration the baseline standard rebates and discounts of new active substance in Greece. Objectives: Liver cancer is one of the most common cancers in Taiwan, with a high incidence and mortality rate. The purpose of this study is to explore the factors that affect the disease burden and medical quality of liver cancer in various hospitals in Taiwan. Methods: This study adopts retrospective research design, taking Taiwan hospitals as the analysis unit. We collected data on the cancer registration files and health insurance database in Taiwan from 2011 to 2016, and calculated the incidence of liver cancer, the severity of the disease, and the one-year survival rate of hospitals throughout Taiwan. This study uses hierarchical linear modeling (HLM) to explore the associations of hospital factors (including hospital level, male patient proportion, mean patient age) and administrative area factors (population density, population ageing, physician-patient ratio) and the demand for liver cancer diagnosis and treatment (incidence, severity of disease) and the medical quality (one-year survival rate) in each hospital. Results: The study found that in terms of the incidence of liver cancer in various hospitals, the higher the hospital level (medical center.regional hospital.regional hospital) and physician-patient ratio, the higher the incidence. In terms of the severity of liver cancer in various hospitals, the higher the hospital level, the lower the severity of the disease. As for the medical quality of liver cancer in various hospitals, the higher the mean patient age, the lower the one-year survival rate. Conclusions: In Taiwan, the incidence of hospital liver cancer is mainly affected by the hospital level and the physician-patient ratio. The severity of liver cancer in hospitals is mainly affected by the hospital level. The survival rate of liver cancer in hospitals is mainly affected by the mean patient age. Objectives: In this dramatic global health crisis, Radiology Units underwent some crucial changes in the daily activity organization to minimize the risk of COVID-19 contamination. This study aimed to assess the impact of COVID-19 on the radiological activity of an Italian cancer hospital. Methods: Radiological procedures performed during the period of 8 weeks of Italian lockdown (9 March̶ 3 May 2020) and the same 2019 period were retrospectively collected and compared. Results: During the lockdown period 4053 patients (for a total of 17793 accesses) attended our institution for diagnostic or therapeutic purposes, 942 out of total patients (1110 accesses) underwent at least one radiological procedure. The Radiology Unit reviewed 1438 outpatients scheduled for radiological examinations, of these 456 patients were postponed (-31,7%): 91.7% because not-urgent, 5.6% declined the appointment, and 1.3% for presence of flu-like symptoms. The maximum reduction of patient's access, referred in particular to the second and third weeks of March. Conversely, in the following weeks a gradually progressive growth of patient's access was observed week after week, probably as a consequence of progressive rearrangement of the activities. Compared to the same 2019 period, the number of procedures decreased respectively of: 26.0% in CT, 34,7% in MRI, 34,8% in X-Ray and 58,5% in US. CT scans were subject to the least decrease compared to the other techniques due to their pivotal role in oncology. In the first month of lockdown the number of CT exams dropped by 29% compared to the average of 2019, while in April and May the reduction was of 23% and 18%, respectively. Conclusions: The COVID-19 outbreak has posed a great challenge to radiology, changing its activity with an overall reduction in the number of procedures performed with consequences still unknown in screening, early diagnosis and management of follow up that have been postponed. Objectives: This study aimed to evaluate the impact of the hospital pharmacy logistic reorganization in an Italian cancer center. Agreements with Local Health Authority (AUSL) centralized warehouse for the vast majority of IRST drug supplies, together with implementation of an Enterprise Resource Planning connected with Electronic Medical Record to track drug storage level were the main pillars of this pharmacy supplying rethinking process. Methods: Key performance indicators were created (evaluating deviations between actual and forecasted consumption, supplying analysis, pharmacy warehouse stocks, drug consumption). Data were retrieved from hospital information systems (2016 to 2018). Time series analysis of monthly orders, stocks and their values (V), was focused on assessing trend and possible cyclic patterns during analysis period: graphs of series decomposition were plotted and seasonality was assessed adopting the method proposed by Ollech and Webel (WO test). Results: In 2018, yearly pharmaceutical expenditure increased by 20% compared to 2016 due to increased number of treated patients (+18%). Over the years, the number of orders and drug supplies through the centralized warehouse has increased causing a drastic reduction in direct purchases from suppliers (-67%). A greater stability of the monthly mean stock have been achieved in the years 2017-18, despite the introduction of 78 new drugs (SD: 290KV in 2016 vs 180KV in 2018). Moreover, analyzing supply data (orders, articles, value), a stabilization of the month-in-month differences (monthly average stock normalized) was observed. No seasonality has been demonstrated for the analyzed series. Conclusions: The reorganization process, resulted in several improvements: pharmacy forecasting process became easier despite the increasing number of therapies; supply planning was optimized through a minimum and maximum stock threshold determination avoiding stock exhaustion and at the same time stabilized inventories. Objectives: A systematic, standardized collection of health outcomes during patient treatment and follow-up is a key step towards an effective and efficient health care system. A holistic approach, integrating all stakeholders' perspectives, is necessary to ensure the best quality care. This project aimed to define a standard set of health outcomes for patients with squamous cell carcinoma of head and neck (SCCHN) management. Methods: The project was led and coordinated by a scientific committee (SC) and comprised: (1) literature review (to identify variables used during SCCHN treatment and follow-up); (2) 1 st -SC meeting (to select those variables to be presented during the nominal groups-NG); (3) four NG (n=36 experts) and four interviews with patients (to reach consensus on the key variables to be included in the standard set); and (4) 2 nd -SC meeting (to review the results of the NG ensuring consensus on those variables where consensus was not reached among them). Results: Experts reached consensus to include in the standard set: treatment-related (treatment intent and type, response to treatment, treatment toxicity/complication, treatment completion), degree of health (performance status, patient-reported health status, pain, dysphonia, feeding and speech limitations, body image alteration, tracheotomy), survival (overall and progression-free survival, cause of death), nutritional (weight, nutritional intervention), and others variables (smoking status, alcohol consumption, patient satisfaction with aftermath care, employment status). Experts agreed to collect at baseline factors that may affect the health outcomes, but which cannot be controlled as part of the management of the condition (case-mix variables) including demographic, tumor-related, clinical and nutritional factors. Conclusions: This project may pave the way to standardize the collection of health outcomes in SCCHN and promote the incorporation of patients' perspective in its management. In turn, the information provided through the systematic compilation of this set of variables may define strategies to achieve high-quality and patientcentered care. 

Methods: This was a retrospective observational study using German claims data. We identified adult patients with at least one inpatient or two confirmed outpatient prostate cancer (PC) diagnoses between 01/01/2014-31/12/ 2018 (inclusion period) and who were newly diagnosed with metastases within 365 days from a PC diagnosis in the inclusion period (index date). Evidence of surgical or medical castration at baseline was required and patients were included if they had evidence of resistance to castration. Patients were dropped if they had prescriptions of mCRPC-specific medication at baseline. Regimen analyses for first line therapy were performed by index year and stratified by age group (,80 vs $80). Results: Among 185 mCRPC patients, first-line regimens included primarily ADT agents (91.9%), abiraterone (35.1%), docetaxel (28.7%), and enzalutamide (4.3%). The percentage of regimens containing docetaxel peaked in 2015 (39.4%) and dropped to 20

The percentage of patients receiving ADT monotherapy decreased from 37.5% in 2014, to 29.4% in 2018, while the combination with abiraterone increased from 30.0% to 44.1%. Docetaxel in combination with ADT was prescribed for 25.0% of patients in 2014 and 14